336 related articles for article (PubMed ID: 25349042)
1. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities.
Simsek C; Karanasos A; Magro M; Garcia-Garcia HM; Onuma Y; Regar E; Boersma E; Serruys PW; van Geuns RJ
EuroIntervention; 2016 Jan; 11(9):996-1003. PubMed ID: 25349042
[TBL] [Abstract][Full Text] [Related]
2. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
3. Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years.
Onuma Y; Honda Y; Asano T; Shiomi H; Kozuma K; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Hanaoka KI; Tanabe K; Okada K; Kitahara H; Ono M; Kusano H; Rapoza R; Simonton C; Popma JJ; Stone GW; Fitzgerald PJ; Serruys PW; Kimura T
JACC Cardiovasc Interv; 2020 Jan; 13(1):116-127. PubMed ID: 31918929
[TBL] [Abstract][Full Text] [Related]
4. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
[TBL] [Abstract][Full Text] [Related]
5. Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study.
Zeng Y; Cavalcante R; Tenekecioglu E; Suwannasom P; Sotomi Y; Collet C; Abdelghani M; Jonker H; Digne F; Horstkotte D; Zehender M; Indolfi C; Saia F; Fiorilli R; Chevalier B; Bolognese L; Goicolea J; Nie S; Onuma Y; Serruys PW;
Int J Cardiovasc Imaging; 2017 Apr; 33(4):441-449. PubMed ID: 28012050
[TBL] [Abstract][Full Text] [Related]
6. Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis at the Stented/Scaffolded Segments and the Proximal and Distal Edges.
Gogas BD; Benham JJ; Hsu S; Sheehy A; Lefer DJ; Goodchild TT; Polhemus DJ; Bouchi YH; Hung OY; Yoo SY; Joshi U; Giddens DP; Veneziani A; Quyyumi A; Rapoza R; King SB; Samady H
JACC Cardiovasc Interv; 2016 Apr; 9(7):728-41. PubMed ID: 27056313
[TBL] [Abstract][Full Text] [Related]
7. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
[TBL] [Abstract][Full Text] [Related]
8. Vasomotor Response to Nitroglycerine Over 5 Years Follow-Up After Everolimus-Eluting Bioresorbable Scaffold Implantation.
Dudek D; Rzeszutko Ł; Onuma Y; Sotomi Y; Depukat R; Veldhof S; Ediebah D; Staehr P; Zasada W; Malinowski KP; Kaluza GL; Serruys PW
JACC Cardiovasc Interv; 2017 Apr; 10(8):786-795. PubMed ID: 28427595
[TBL] [Abstract][Full Text] [Related]
9. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data.
Bourantas CV; Serruys PW; Nakatani S; Zhang YJ; Farooq V; Diletti R; Ligthart J; Sheehy A; van Geuns RJ; McClean D; Chevalier B; Windecker S; Koolen J; Ormiston J; Whitbourn R; Rapoza R; Veldhof S; Onuma Y; Garcia-Garcia HM
EuroIntervention; 2015 Nov; 11(7):746-56. PubMed ID: 25308301
[TBL] [Abstract][Full Text] [Related]
10. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
[TBL] [Abstract][Full Text] [Related]
11. Analysis of 1 year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.
Brugaletta S; Gomez-Lara J; Garcia-Garcia HM; Heo JH; Farooq V; van Geuns RJ; Chevalier B; Windecker S; McClean D; Thuesen L; Whitbourn R; Meredith I; Dorange C; Veldhof S; Rapoza R; Ormiston JA; Serruys PW
Int J Cardiovasc Imaging; 2012 Aug; 28(6):1307-14. PubMed ID: 22108907
[TBL] [Abstract][Full Text] [Related]
12. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
13. Scaffold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a 3-year serial optical coherence tomography study.
Zhang YJ; Iqbal J; Nakatani S; Bourantas CV; Campos CM; Ishibashi Y; Cho YK; Veldhof S; Wang J; Onuma Y; Garcia-Garcia HM; Dudek D; van Geuns RJ; Serruys PW;
JACC Cardiovasc Interv; 2014 Dec; 7(12):1361-9. PubMed ID: 25457053
[TBL] [Abstract][Full Text] [Related]
14. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
[TBL] [Abstract][Full Text] [Related]
15. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
[TBL] [Abstract][Full Text] [Related]
16. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S
JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155
[TBL] [Abstract][Full Text] [Related]
17. Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical coherence tomography evaluation and clinical outcomes.
Kochman J; Tomaniak M; Pietrasik A; Kołtowski Ł; Rdzanek A; Huczek Z; Mazurek T; Jąkała J; Ząbek A; Legutko J; Kochman W; Filipiak KJ
Cardiol J; 2015; 22(3):315-22. PubMed ID: 25428734
[TBL] [Abstract][Full Text] [Related]
18. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
Serruys PW; Ormiston J; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Chevalier B; Smits P; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Wasungu L; Ediebah D; Veldhof S; Onuma Y
J Am Coll Cardiol; 2016 Feb; 67(7):766-76. PubMed ID: 26892411
[TBL] [Abstract][Full Text] [Related]
19. Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study.
Toušek P; Kočka V; Malý M; Lisa L; Buděšínský T; Widimský P
Heart Vessels; 2016 Jun; 31(6):841-5. PubMed ID: 25896128
[TBL] [Abstract][Full Text] [Related]
20. Serial Assessment of Tissue Precursors and Progression of Coronary Calcification Analyzed by Fusion of IVUS and OCT: 5-Year Follow-Up of Scaffolded and Nonscaffolded Arteries.
Zeng Y; Tateishi H; Cavalcante R; Tenekecioglu E; Suwannasom P; Sotomi Y; Collet C; Nie S; Jonker H; Dijkstra J; Radu MD; Räber L; McClean DR; van Geuns RJ; Christiansen EH; Fahrni T; Koolen J; Onuma Y; Bruining N; Serruys PW
JACC Cardiovasc Imaging; 2017 Oct; 10(10 Pt A):1151-1161. PubMed ID: 28330651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
